MS Franchise A Surprising Concern For Sanofi In Q3; Dupixent Out-Performs

 
• By Lucie Ellis-Taitt

Sanofi produced a mixed financial performance in the third quarter of 2017, with reported sales more than €200m below analysts' expectations but new drug Dupixent doing well; MS drug sales have fallen since Q2 by more than €50m.

Pressure
Sanofi MS franchise under pressue after disappointing growth in Q3 • Source: Shutterstock

More from Earnings

More from Business